Alnylam Pharmace. buy melinda
Start price
28.09.18
/
50%
€81.26
Target price
22.01.19
€95.61
Performance (%)
-10.01%
End price
22.01.19
€73.13
Summary
This prediction ended on 22.01.19 with a price of €73.13. The prediction for Alnylam Pharmace. disappointed with a performance of -10.01%. melinda has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | -1.217% | -1.217% | -25.196% | 18.653% |
| iShares Core DAX® | 2.594% | -1.158% | 14.782% | 16.813% |
| iShares Nasdaq 100 | 3.553% | -1.727% | 43.265% | 44.227% |
| iShares Nikkei 225® | 0.687% | -8.354% | 18.454% | 1.361% |
| iShares S&P 500 | 2.209% | -0.942% | 31.361% | 42.812% |
According to melinda what are the pros and cons of Alnylam Pharmace. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Alnylam Pharmace. diskutieren
SecteurRecherche biotechnologique et médicale Agenda 07/11 Publication de résultats
Développements basés sur l'interférence de l'ARN Alnylam Pharmaceuticals, Inc. est une société biopharmaceutique spécialisée dans la découverte, le développement et la commercialisation de produits thérapeutiques à base d'ARNi.
Il s'agit de la traduction de l'ARNi en tant que nouvelle classe de médicaments innovants, centrée sur les thérapies ARNi pour le traitement de maladies génétiquement définies.
La société a été fondée par John Kennedy Clarke, Paul R. Schimmel et Phillip A. Sharp le 14 juin 2002 et a son siège à Cambridge, dans le Massachusetts.
Nombre d'employés : 749 personnes.
(Vom Mitglied beendet)
Stopped prediction by melinda for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€180.85
16.10.21
16.10.21
€160.00
16.10.22
16.10.22
-6.22%
24.10.21
24.10.21
Could be worthwhile Investment >10% per year
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€109.44
27.11.19
27.11.19
-
04.11.21
04.11.21
65.25%
16.10.21
16.10.21
Could be worthwhile Investment >10% per year
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€128.12
12.03.18
12.03.18
€144.32
13.09.18
13.09.18
-33.29%
13.09.18
13.09.18
Could be worthwhile Investment >10% per year
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€113.81
16.11.17
16.11.17
€126.28
12.03.18
12.03.18
11.75%
12.03.18
12.03.18
Could be worthwhile Investment >10% per year
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€102.68
20.09.17
20.09.17
€125.38
10.11.17
10.11.17
22.22%
10.11.17
10.11.17
Could be worthwhile Investment >10% per year
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€113.84
20.09.17
20.09.17
€139.00
10.11.17
10.11.17
22.22%
10.11.17
10.11.17
Could be worthwhile Investment >10% per year
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€75.00
09.09.17
09.09.17
€85.00
20.09.17
20.09.17
30.03%
20.09.17
20.09.17
Could be worthwhile Investment >10% per year
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€67.65
09.09.17
09.09.17
€76.67
20.09.17
20.09.17
30.03%
20.09.17
20.09.17
Could be worthwhile Investment >10% per year
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€47.11
24.09.13
24.09.13
€52.00
24.03.14
24.03.14
8.26%
24.03.14
24.03.14
Could be worthwhile Investment >10% per year